Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years

Peritoneal Dialysis International

Volumn 20, Issue 2, 2000, Pages 174-180

  Posthuma, Nynke ^a,f   Verbrugh, Henri A ^b   Donker, Ab J M ^a   Van Dorp, Wim ^c   Dekker, Hubertina A Th ^d   Peers, Elizabeth M ^e   Oe, Po L ^a   Ter Wee, Pieter M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Infection and Immunology   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Vrije Universiteit ^*  (United Kingdom)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Biocompatibility; CA125; Icodextrin; Interleukin 8; Mass transfer area coefficient; Mesothelium; Procollagen

Indexed keywords

GLUCAN; GLUCOSE; HEMODIALYSIS FLUID; ICODEXTRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITHELIUM; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; ULTRAFILTRATION;

ADULT; AGED; EPITHELIUM; FEMALE; GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; TIME FACTORS; ULTRAFILTRATION;

EID: 0034154833     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002000203     Document Type: Article

References (35)

1. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7:74-85.
2. Dobbie JW. Durability of the peritoneal membrane. Perit Dial Int 1995; 15(7, Suppl):S87-91.
3. Hjelle JT, Miller-Hjelle MA, Dobbie JW. The biology of the mesothelium during peritoneal dialysis. Perit Dial Int 1995; 15(7, Suppl):S13-22.
4. Krediet RT, Ho-dac-Pannekeet MM, Struijk DG. Preservation of peritoneal membrane function. Kidney Int 1996; 50(Suppl 56):S62-8.
5. Williams JD. Biocompatibility in peritoneal dialysis: definitions and mechanisms. Perit Dial Int 1995; 15(7, Suppl):S5-8.
6. Davies DS. Kinetics of icodextrin. Perit Dial Int 1994; 14(Suppl 2):S45-50.
7. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Kidney Int 1994; 46:496-503.
8. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988; 34:715-18.
9. Nagy JA. Peritoneal membrane morphology and func-tion. Kidney Int 1996; 50(Suppl 56):S2-11.
10. Zeillemaker AM, Mul FP, Hoynck van Papendrecht AA, Leguit P, Verbrugh HA, Roos D. Neutrophil adherence to and migration across monolayers of human peritoneal mesothelial cells. The role of mesothelium in the influx of neutrophils during peritonitis. J Lab Clin Med 1996; 127:279-86.
11. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550-3.
12. Posthuma N, ter Wee PM, Donker AJM, Oe PL, van Dorp W, Peers EM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997; 17:602-7.
13. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
14. Pannekeet MM, Imholz AL, Struijk DG, Koomen GC, Langedijk MJ, Schouten N, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
15. Krediet RT, Struijk DG, Koomen GC, Arisz L. Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991; 37:662-7.
16. Krediet RT, Boeschoten EW, Zuyderhoudt FM, Strackee J, Arisz L. Simple assessment of the efficacy of peritoneal transport in continuous ambulatory peritoneal dialysis patients. Blood Purif 1986; 4:194-203.
17. Garred LJ, Canaud B, Farrell PC. A simple kinetic model for assessing peritoneal mass transfer in chronic ambulatory peritoneal dialysis. ASAIO J 1983; 6:131-7.
18. Imholz AL, Koomen GC, Struijk DG, Arisz L, Krediet RT. Residual volume measurements in CAPD patients with exogenous and endogenous solutes. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8:33-8.
19. Koomen GC, Krediet RT, Leegwater AC, Struijk DG, Arisz L, Hoek FJ. A fast reliable method for the measurement of intraperitoneal dextran 70, used to calculate lymphatic absorption. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1991; 7:10-14.
20. Stegeman G, de Waart DR, Hiralall K, Krediet RT, Arisz L, Hoek FJ. Measurement of dextran 70 in peritoneal dialysate containing icodextrin. Perit Dial Int 1995; 15(Suppl 2):S18.
21. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1988; 36:1328-32.
22. Verbrugh HA, van Bronswijk H, van der Meulen J, Oe PL, Verhoef J. Phagocytic defence against CAPD peritonitis. The bacterium, the phagocyte, and the doctor. Contrib Nephrol 1987; 57:85-91.
23. van Bronswijk H, Verbrugh HA, Bos HJ, Heezius EC, Oe PL, van der Meulen J, et al. Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989; 9:197-202.
24. Breborowicz A, Karon J, Korybalska K, Martis L, Oreopoulos DG. Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1995; 11:15-18.
25. Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996; 49:1447-56.
26. Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1990; 6:3-12.
27. Gotloib L, Bar-Sella P, Shostak A. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 1985; 5:212-15.
28. Di Paolo N and Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9:41-5.
29. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik D. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445-51.
30. Mahiout A, Ehlerding G, Brunkhorst R. Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrol Dial Transplant 1996; 11(Suppl 5):2-6.
31. Struijk DG, Krediet RT, Koomen GC, Boeschoten EW, Hoek FJ, Arisz L. A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994; 45: 1739-44.
32. Pannekeet MM, Koomen GC, Struijk DG, Krediet RT. Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Clin Nephrol 1995; 44: 248-54.
33. Simonsen O, Wieslander A, Landgren C, Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1996; 12: 156-60.
34. Graff J, Joffe P, Fugleberg S, Jensen LT. Collagen markers in peritoneal dialysis patients. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1995; 11:24-7.
35. Joffe P and Jensen LT. Type I and III procollagens in CAPD: markers of peritoneal fibrosis. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1991; 7:158-60.